Bayer says darolutamide shown to slow prostate cancer progression
17/07/2024 06:40
FRANKFURT, July 17 (Reuters) - Bayer BAYGn.DE said on
Wednesday its drug candidate darolutamide was shown to slow the
progression of certain types of prostate cancer in a late-stage
trial.
Bayer is working on darolutamide jointly with Filand's Orion
ORNBV.HE .
(Reporting by Ludwig Burger, Editing by Rachel More)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))